The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...

FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026HREC Approval ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

New study in Nature Reviews Drug Discovery shows late-stage failure rates have doubled since 2013, shifting from scientific ...

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and develop differentiated ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer's drug—are poised ...

Early-phase clinical trials, those first-in-human studies, are where years of research and millions in investment meet the ...

– Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism ...

Avinasi Labs Enables a New Funding & Revenue Model for Clinical Stage Assets via DeLong Protocol SAN FRANCISCO, CA, UNITED STATES, December 31, 2025 /EINPresswire.com/ — Avinasi Labs, an AI-native ...

Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) ...